What is CD117?
CD117, also known as
c-Kit or stem cell factor receptor (SCFR), is a type of protein that functions as a receptor tyrosine kinase. This protein is encoded by the
KIT gene and plays a crucial role in cell signaling, proliferation, differentiation, and survival. It is expressed on the surface of various cell types, including
hematopoietic stem cells, mast cells, and certain types of cancer cells.
How is CD117 Detected?
CD117 is typically detected using
immunohistochemistry (IHC), a technique that employs antibodies to detect specific antigens in tissue sections. The primary antibody binds to CD117, and a secondary antibody conjugated with a detectable marker (such as an enzyme or fluorescent dye) binds to the primary antibody. This allows for the visualization of CD117 expression in tissue samples. Other methods, such as
flow cytometry and
Western blotting, can also be used to detect CD117 expression.
Gastrointestinal Stromal Tumors (GISTs): CD117 is highly expressed in GISTs, making it a valuable diagnostic marker for these tumors.
Mastocytosis: Elevated levels of CD117 are found in mast cells in conditions like systemic mastocytosis and cutaneous mastocytosis.
Acute Myeloid Leukemia (AML): CD117 is expressed in certain subtypes of AML, aiding in the diagnosis and classification of the disease.
Melanoma: CD117 expression can be observed in some cases of melanoma, although it is less common.
What is the Role of CD117 in Cancer?
CD117 plays a significant role in the development and progression of certain cancers. It can promote cell proliferation, survival, and migration, contributing to tumor growth and metastasis. In GISTs, activating mutations in the KIT gene lead to constitutive activation of the CD117 receptor, driving tumor development. Targeted therapies, such as
imatinib, have been developed to inhibit the activity of CD117 in these tumors, improving patient outcomes.
Can CD117 be Targeted for Therapy?
Yes, CD117 can be targeted for therapy, particularly in cancers where it plays a critical role. Inhibitors of CD117, such as
tyrosine kinase inhibitors (TKIs) like imatinib, are used to treat GISTs and other malignancies with aberrant CD117 signaling. These therapies work by blocking the kinase activity of CD117, thereby inhibiting cell proliferation and inducing apoptosis in cancer cells.
Heterogeneity of Expression: CD117 expression can vary widely among different cell types and tumors, making it challenging to develop universal diagnostic and therapeutic strategies.
Resistance to Therapy: Some tumors develop resistance to TKIs, necessitating the development of new therapeutic approaches.
Technical Variability: Variations in immunohistochemical techniques and antibody specificity can affect the accuracy and reproducibility of CD117 detection.